Plasma exchange for acute renal failure of myeloma - Logical, yet ineffective

Journal of the American Society of Nephrology

Volumn 17, Issue 4, 2006, Pages 914-916

  Ritz, Eberhard ^a  

^a Division of Nephrology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYTOTOXIC AGENT; DOXORUBICIN; METHYLPREDNISOLONE; VINCRISTINE;

ACUTE KIDNEY FAILURE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIURESIS; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; MYELOMA; NOTE; PATIENT DECISION MAKING; PERITONEAL DIALYSIS; PLASMAPHERESIS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SURVIVAL; TREATMENT OUTCOME;

EID: 33645464856     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (26)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 55: 10-30, 2005
2. Gertz MA: Managing myeloma kidney. Ann Intern Med 143: 835-837, 2005
3. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR: Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78: 21-33, 2003
4. Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S, Cases A, Darnell A, Rozman C, Montserrat E: Renal failure in multiple myeloma: Presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 158: 1889-1893, 1998
5. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J: Renal function in newly diagnosed multiple myeloma-A demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 53: 207-212, 1994
6. MacLennan IC, Cooper EH, Chapman CE, Kelly KA, Crockson RA: Renal failure in myelomatosis. Eur J Haematol Suppl 51: 60-65, 1989
7. Pozzi C, Pasquali S, Donini U, Casanova S, Banfi G, Tiraboschi G, Furci L, Porri MT, Ravelli M, Lupo A, et al: Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma: A review of 50 cases. Report of the Italian Renal Immunopathology Group. Clin Nephrol 28: 1-9, 1987
8. Misiani R, Remuzzi G, Bertani T, Licini R, Levoni P, Crippa A, Mecca G: Plasmapheresis in the treatment of acute renal failure in multiple myeloma. Am J Med 66: 684-688, 1979
9. Zucchelli P, Pasquali S, Cagnoli L, Ferrari G: Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 33: 1175-1180, 1988
10. Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE: Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 150: 863-869, 1990
11. Kaplan AA: Therapeutic apheresis for the renal complications of multiple myeloma and the dysglobulinemias. Ther Apher 5: 171-175, 2001
12. Kaplan AA: The use of apheresis in immune renal disorders. Ther Apher Dial 7: 165-172, 2003
13. El-Achkar TM, Sharfuddin AA, Dominguez J: Approach to acute renal failure with multiple myeloma: Role of plasmapheresis. Ther Apher Dial 9: 417-422, 2005
14. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B: Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 4: 379-398, 2003
15. Smith JW, Weinstein R; for the AHCKL: Therapeutic apheresis: A summary of current indication categories endorsed by the AABB and the American Society for Apheresis. Transfusion 43: 820-822, 2003
16. Knudsen LM, Hjorth M, Hippe E: Renal failure in multiple myeloma: Reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 65: 175-181, 2000
17. Sirohi B, Powles R, Kulkarni S, Rudin C, Saso R, Rigg A, Horton C, Singhal S, Mehta J, Treleaven J: Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma. Br J Cancer 85: 325-332, 2001
18. Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, Heidenheim AP, Garg AX, Churchill DN: Plasma exchange when myeloma presents as acute renal failure: A randomized, controlled trial. Ann Intern Med 143: 777-784, 2005
19. Montseny JJ, Kleinknecht D, Meyrier A, Vanhille P, Simon P, Pruna A, Eladari D: Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant 13: 1438-1445, 1998
20. Herrera GA, Joseph L, Gu X, Hough A, Barlogie B: Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med 128: 875-879, 2004
21. Cohen AH: The kidney in plasma cell dyscrasias: Bence-Jones cast nephropathy and light chain deposit disease. Am J Kidney Dis 32: 529-532, 1998
22. Torra R, Blade J, Cases A, Lopez-Pedret J, Montserrat E, Rozman C, Revert L: Patients with multiple myeloma requiring long-term dialysis: Presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 91: 854-859, 1995
23. Pozzi C, D'Amico M, Fogazzi GB, Curioni S, Ferrario F, Pasquali S, Quattrocchio G, Rollino C, Segagni S, Locatelli F: Light chain deposition disease with renal involvement: Clinical characteristics and prognostic factors. Am J Kidney Dis 42: 1154-1163, 2003
24. Pichette V, Querin S, Desmeules M, Ethier J, Copleston P: Renal function recovery in end-stage renal disease. Am J Kidney Dis 22: 398-402, 1993
25. Rayner HC, Haynes AP, Thompson JR, Russell N, Fletcher J: Perspectives in multiple myeloma: Survival, prognostic factors and disease complications in a single centre between 1975 and 1988. Q J Med 79: 517-525, 1991
26. Haubitz M. Peest D: Myeloma-New approaches to combined nephrological-hematological management. Nephrol Dial Transplant 21, 2006